Is Thermo Fisher Scientific Stock Outperforming the Nasdaq?

Valued at a market cap of $230 billion, Thermo Fisher Scientific Inc. (TMO) is a global leader in serving the life sciences industry, providing the tools, technologies, diagnostics, laboratory supplies, and outsourced services to conduct research, develop medicines, and improve patient care. The Waltham, Massachusetts-based company portfolio spans reagents and consumables, analytical and laboratory instruments, genetic and molecular biology technologies, diagnostic products, and biopharmaceutical development and manufacturing services.

Companies valued at $200 billion or more are generally classified as “mega-cap” stocks, and Thermo Fisher Scientific fits this criterion perfectly. 

The company's shares have fallen 3.8% from its 52-week high of $647. TMO stock has declined 27.7% over the past three months, notably underperforming the Nasdaq Composite’s ($NASX) 1.9% fall 

The stock is up 7.4% on a YTD basis, lagging behind NASX’s nearly 13.6% rise. In the longer term, however, shares of Thermo Fisher Scientific have soared 27% over the past 52 weeks, outpacing the index’s 21.6% return over the same time frame.

The stock has been trading above its 50-day moving average since late June and over its 200-day moving average since mid-July. 

Thermo Fisher Scientific has outpaced the broader market over the past year as improving life-sciences demand, strong execution, and accelerating earnings growth have strengthened investor confidence. The company has benefited from a recovery in biotech and pharmaceutical research spending, while broad-based growth across its businesses has supported higher revenue and expanding margins. Its better-than-expected recent quarterly results and raised 2026 outlook have further reinforced expectations for sustained growth. 

However, TMO stock has outperformed its rival, Danaher Corporation (DHR). DHR stock has dropped 5.6% on a YTD basis and nearly 5.3% rally over the past 52 weeks. 

Analysts remain strongly optimistic about its prospects. The stock has a consensus rating of “Strong Buy” from 26 analysts' coverage, and the mean price target of $636.56 is a premium of 2.3% to current levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.